Network Meta-Analysis of Triple Therapy in participants with Uncontrolled Asthma
Trial overview
Difference in Change from Baseline (DCFB) in Trough Forced Expiratory Volume in One Second (FEV1) at 24 Weeks
Timeframe: At 24 weeks from treatment initiation
Incidence Rate Ratio (IRR) for Annualized Rate of Moderate/Severe Exacerbations at 52 Weeks
Timeframe: At 52 weeks from treatment initiation
DCFB for Asthma Control Questionnaire (ACQ)-7 Total Score at 24 Weeks
Timeframe: At 24 weeks from treatment initiation
Difference in Post-treatment Total Score of ACQ-7 at 24 Weeks
Timeframe: At 24 weeks from treatment initiation
Odds Ratio (OR) for ACQ-7 Responder Rate at 24 Weeks
Timeframe: At 24 weeks from treatment initiation
DCFB for AQLO Total Score at 24 Weeks
Timeframe: At 24 weeks from treatment initiation
- Participants with a diagnosis of asthma; Moderate to severe asthma, Severe asthma, e.g., refractory asthma or difficult-to-treat asthma, Persistent asthma.
- Participants whose asthma is inadequately controlled despite treatment with ICS/LABA therapy. Proportion of participants receiving ICS/LABA at Baseline greater than or equal to (>=) 70 percent.
- Studies only conducted in participants less than (<) 18 years of age; studies where participants mean age <=17 years, Proportion of adults participants (aged 18+) is <75 percent of the total participant Population.
- Participants with a diagnosis of chronic obstructive pulmonary disease (COPD).
- Participants with a diagnosis of asthma; Moderate to severe asthma, Severe asthma, e.g., refractory asthma or difficult-to-treat asthma, Persistent asthma.
- Participants whose asthma is inadequately controlled despite treatment with ICS/LABA therapy. Proportion of participants receiving ICS/LABA at Baseline greater than or equal to (>=) 70 percent.
- Adults (18 years or older).
- Tiotropium plus (+) all ICS/LABA therapies
- Tiotropium + fluticasone + salmeterol
- Budesonide + glycopyrrolate + formoterol
- Glycopyrronium + fluticasone + salmeterol
- Fluticasone + umeclidinium + vilanterol
- Beclometasone + formoterol + glycopyrronium
- Umeclidinium + fluticasone + salmeterol
- Any ICS-LABA vs. ICS-LABA dual therapies in one single inhaler or multiple inhalers
- Mean change from baseline in lung function endpoints: peak Forced Expiratory Volume in 1 second (FEV1)
- Annualized rate and number of participants with total (moderate and severe), moderate or severe asthma exacerbations, and proportion of participants by number of exacerbations (e.g. exacerbation categories of 0, 1, 2+)
- Time to first moderate and/or severe asthma exacerbations
- Mean change of total score from baseline in asthma control (Asthma Control Test [ACT] or Asthma Control Questionnaire [ACQ])
- Proportion of participants achieving clinical remission. Defined as meeting all 4, or the first 3 of the following components: free from OCS use (including maintenance OCS and includes oral, intravenous and subcutaneous steroids.); no severe exacerbations (as defined in CAPTAIN); ACQ-5 total score less than or equal to (<=) 1.5; change from baseline in trough FEV1 >= 100 milliliters (mL)
- Randomized controlled trials (RCT) will be included (Phase II, III, and IV).
- RCT extension studies (as long as randomization has not been broken)
- Pragmatic trials
- Conference proceedings that report original data
- Systematic reviews of interest will be included for reference checks
- Other considerations will include any language, no limit to geographical location or time horizon, or studies where the trial duration was shorter than 8 weeks will be included in the systematic literature review (SLR) but not to be extracted
Studies reporting any combination of ICS, long-acting muscarinic antagonist (LAMA), and LABA triple therapies in one single inhaler or multiple inhalers, e.g.,
Studies with any dual versus dual therapies
Studies reporting asthma-related outcomes including clinical, efficacy, safety, quality of life, and resource use measures:
- Studies only conducted in participants less than (<) 18 years of age; studies where participants mean age <=17 years, Proportion of adults participants (aged 18+) is <75 percent of the total participant Population.
- Participants with a diagnosis of chronic obstructive pulmonary disease (COPD).
- Mixed Population (for e.g., Asthma and COPD) with no results for asthma participant Population.
- Studies with following interventions will be excluded; No ICS/LAMA/LABA triple combination therapies or dual ICS/LABA therapies in the clinical trials, Mono versus dual ICS/LABA therapies, Mono versus mono therapies, Biologics and leukotriene receptor antagonists (LTRAs) are not relevant treatment arms, Single maintenance and reliever therapy (SMART) is not relevant treatment arm and ICS in combination with a LAMA is not a relevant treatment arm.
- Studies reporting outcomes anything other than the listed ones for inclusion will be excluded.
- Single-arm trials, Observational studies, Phase I study, Practical clinical trials, Cross-sectional studies, Follow-up studies, Longitudinal studies, Case-control studies, Prospective cohort studies, Retrospective cohort studies, Registry-based studies, Database-based studies, Clinical drug evaluations, Narrative reviews, Economic models, Case reports, Letter/ Editorial/ Commentary/ News, Historical articles and Animal studies will be excluded.
- Any conference proceeding before 2018
Trial location(s)
No location data available.
Study documents
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.